EBS Emergent Biosolutions Inc.

+1.37  (+3%)
Previous Close 51.59
Open 51.57
Price To Book 2.69
Market Cap 2721214764
Shares 51,382,454
Volume 675,024
Short Ratio 4.57
Av. Daily Volume 572,332

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 9, 2017. Completion due 2019.
Influenza A
Approved May 17, 2012.
Anthrax Vaccine
Approved November 24, 2015.
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Phase 2b data due mid-2019.
End-stage renal disease
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
Zika vaccine
Phase 3 trial planned for 2019.
Anthrax vaccine
Phase 2 interim analysis April 16, 2019.
Chikungunya virus

Latest News

  1. Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
  2. Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
  3. Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
  4. What Should We Expect From Emergent BioSolutions Inc.'s (NYSE:EBS) Earnings In The Year Ahead?
  5. Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
  6. See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
  7. Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?
  8. Emergent Begins Phase III Study on Anthrax Vaccine AV7909
  9. Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
  10. Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
  11. The Emergent BioSolutions (NYSE:EBS) Share Price Has Gained 111%, So Why Not Pay It Some Attention?
  12. Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT
  13. Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
  14. Emergent BioSolutions Looks to Break $1 Billion
  15. Emergent BioSolutions Inc (EBS) Files 10-K for the Fiscal Year Ended on December 31, 2018
  16. Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
  17. Emergent Biosolutions Inc (EBS) Q4 2018 Earnings Conference Call Transcript
  18. Emergent Biosolutions (EBS) Q4 Earnings and Revenues Surpass Estimates
  19. Emergent Biosolutions: 4Q Earnings Snapshot